Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cash from Financing Activities (2016 - 2026)

Catalyst Pharmaceuticals filings provide 16 years of Cash from Financing Activities readings, the most recent being -$12.9 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities fell 520.65% to -$12.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$32.9 million, a 1330.42% decrease, with the full-year FY2025 number at -$17.0 million, down 112.08% from a year prior.
  • Cash from Financing Activities hit -$12.9 million in Q1 2026 for Catalyst Pharmaceuticals, up from -$25.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $141.0 million in Q1 2024 to a low of -$25.6 million in Q4 2025.
  • Median Cash from Financing Activities over the past 5 years was $149000.0 (2023), compared with a mean of $6.0 million.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 925.0% in 2022 and later skyrocketed 94563.76% in 2024.
  • Catalyst Pharmaceuticals' Cash from Financing Activities stood at $2.3 million in 2022, then crashed by 129.52% to -$665000.0 in 2023, then soared by 766.62% to $4.4 million in 2024, then plummeted by 677.04% to -$25.6 million in 2025, then soared by 49.68% to -$12.9 million in 2026.
  • The last three reported values for Cash from Financing Activities were -$12.9 million (Q1 2026), -$25.6 million (Q4 2025), and $4.7 million (Q3 2025) per Business Quant data.